Andrew J. Lightfoot

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer

Andrew J. Lightfoot, Benjamin N. Breyer, Henry Rosevear et al. · Urologic Oncology Seminars and Original Investigations · 2013 · 122 citations

Mitomycin C Chemotherapy, Urology, Urologic Cancer Epidemiology +8

Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer

Kenneth G. Nepple, Andrew J. Lightfoot, Henry Rosevear et al. · The Journal of Urology · 2010 · 120 citations

Utility of the RENAL nephrometry scoring system in the real world: predicting surgeon operative preference and complication risk

Henry Rosevear, Paul T. Gellhaus, Andrew J. Lightfoot et al. · British Journal of Urology · 2011 · 99 citations

Factors Affecting Response to Bacillus Calmette-Guérin Plus Interferon for Urothelial Carcinoma in Situ

Henry Rosevear, Andrew J. Lightfoot, Kevin K. Birusingh et al. · The Journal of Urology · 2011 · 50 citations

Calmette-guérin Plus Interferon, Microbial Pathogens, Bacteriology +23

Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy

Lyse A. Norian, Timothy P. Kresowik, Henry Rosevear et al. · PLoS ONE · 2012 · 50 citations · Full text

Urology, Metastatic Murine Rcc, Cancer Immunosurveillance +15